Multiple sclerosis is a chronic disease of the central nervous system that affects nearly one million people in the U.S. alone. Biotech companies are working to expand therapeutic options for the disease, which is currently treated with disease-modifying drugs. Several companies, including Biogen, Immunic Therapeutics, Kyverna Therapeutics, Progentos Therapeutics, TG Therapeutics, and Zenas BioPharma, are developing new treatments for multiple sclerosis, including BTK inhibitors, CAR-T therapies, and bispecific antibodies. These advancements are expected to improve the lives of patients with multiple sclerosis.
Forecast for 6 months: Expect to see the initiation of phase 3 trials for several new multiple sclerosis treatments, including vidofludimus calcium and KYV-101.
Forecast for 1 year: At least one new multiple sclerosis treatment is expected to receive FDA approval, marking a significant breakthrough in the field.
Forecast for 5 years: The global multiple sclerosis drug market is projected to grow from $21.16 billion in 2024 to $38.94 billion by 2032, with several new treatments expected to be available for patients.
Forecast for 10 years: Multiple sclerosis is expected to become a manageable disease, with patients able to live normal lives with minimal symptoms, thanks to the advancements in treatment options.
